Cero Therapeutics regains compliance with Nasdaq

CERo Therapeutics (CERO) Holdings announces it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires minimum stockholders’ equity of $2.5 million. On May 7, 2025 the Nasdaq Hearings Panel notified the Company that following the execution of its private placement of Series D Preferred Stock on 4/21/2025, a partial drawdown from the Company’s Equity Line of Credit, and the closing of a public offering in February 2025, the Panel has determined that the Company now complies with the Equity Rule.